With Latest RA Deal, Janssen Seeks To Improve Outcomes With Small Molecules
This article was originally published in The Pink Sheet Daily
Janssen gets option to Modern’s small-molecule candidates for rheumatoid arthritis that could address both the inflammatory and bone-damaging effects of the disease. An R&D exec says the compounds could be complementary to, or used in combination with, Remicade and Simponi, or as standalone RA therapies.
You may also be interested in...
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for.